The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug an...

Descripción completa

Detalles Bibliográficos
Autores principales: G. de la Torre, Beatriz, Albericio, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412490/
https://www.ncbi.nlm.nih.gov/pubmed/30813407
http://dx.doi.org/10.3390/molecules24040809
_version_ 1783402617282494464
author G. de la Torre, Beatriz
Albericio, Fernando
author_facet G. de la Torre, Beatriz
Albericio, Fernando
author_sort G. de la Torre, Beatriz
collection PubMed
description The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules.
format Online
Article
Text
id pubmed-6412490
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64124902019-04-09 The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules G. de la Torre, Beatriz Albericio, Fernando Molecules Review The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules. MDPI 2019-02-23 /pmc/articles/PMC6412490/ /pubmed/30813407 http://dx.doi.org/10.3390/molecules24040809 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
G. de la Torre, Beatriz
Albericio, Fernando
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_full The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_fullStr The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_full_unstemmed The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_short The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
title_sort pharmaceutical industry in 2018. an analysis of fda drug approvals from the perspective of molecules
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412490/
https://www.ncbi.nlm.nih.gov/pubmed/30813407
http://dx.doi.org/10.3390/molecules24040809
work_keys_str_mv AT gdelatorrebeatriz thepharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT albericiofernando thepharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT gdelatorrebeatriz pharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules
AT albericiofernando pharmaceuticalindustryin2018ananalysisoffdadrugapprovalsfromtheperspectiveofmolecules

Ejemplares similares